Notably, our previous work demonstrated that bemcentinib, a selective AXL inhibitor, mitigates experimental renal fibrosis by reducing p‐EMT induction, inflammation, and downregulating genes associated with fibrosis in a unilateral ureteral obstruction (UUO) mouse model (Landolt et al., 2019). The gene discussed is AXL; the disease is renal fibrosis.